Navigation Links
Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
Date:9/6/2013

AQUEBOGUE, N.Y., Sept. 6, 2013 /PRNewswire/ -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling a total of nine (9) lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution,  30 mL, to the consumer level. There have been no reports of adverse effects to consumers so far.  However, due to complaints of mold found in the 30 mL bottles after use, concerns regarding the effectiveness of the preservative after use and handling of the product by consumers have prompted the recall.

A product whose preservative is not effective could lead to use of a contaminated product which could be calamitous for any population since there is a reasonable probability of a potentially sight threatening eye infection.  It has been confirmed by Altaire that all lots of product were sterile at the time of release, and that the preservative was effective when challenged against the USP Preservative Effectiveness Test.  It has also been confirmed by Altaire that its production facility is not the source of any reported contaminants.

The product is known generically as Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution and labeled as follows:

  • equate Restore Tears Lubricant Eye Drops Carboxymethylcellulose Sodium 0.5%, Sterile, 1 FL OZ (30 mL) - Distributed by Wal-Mart Stores, Inc.;
  • Lubricant EYE DROPS FOR MILD TO MODERATE DRY EYE, STERILE, 1 FL OZ (30 mL), for Mild to Moderate Dry Eye - Distributed by CVS Pharmacy, Inc.;
  • lubricant eye drops for mild to moderate dry eye, STERILE, 1 FL OZ (30 mL) -  Dist. by Target Corp.  

Only the lots listed below are affected, and the recall is limited to the product in the 30 mL size

  • Lot # 11440, expiration date  09/2013, labeled for CVS;
  • Lot # 11441, expiration date  09/2013, labeled for CVS;
  • Lot # 12042, expiration date 01/2014, labeled for Wal-Mart and CVS; 
  • Lot # 12103, expiration date 02/2015, labeled for Wal-Mart;
  • Lot # 12203, expiration date 05/2015, labeled for Wal-Mart and CVS; 
  • Lot # 12207, expiration date 05/2015, labeled for Wal-Mart;
  • Lot # 12293, expiration date 08/2015, labeled for Wal-Mart; 
  • Lot # 12352, expiration date 09/2015, labeled for Target and CVS;
  • Lot # 12356, expiration date 09/2015, labeled for Target and CVS. 

Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution is a non-prescription (OTC) drug product used to relieve dryness of the eye and packaged in a plastic bottle inside a unit box.  Lot numbers can be found printed horizontally on the side of the label and on the bottom flap of the box.   The lots listed above were distributed between February 2012 and April 2013.   The product was sold nationwide at retail stores.

Altaire Pharmaceuticals is initiating the recall as a precautionary measure.  Altaire takes its mission of consumer care and providing quality products very seriously.  The company has reformulated the product with an enhanced preservative system.  All lots of the product in the 30 mL size identified with lot numbers beginning with 13 (i.e. 13000) have been made with the enhanced preservative system. 

Altaire Pharmaceuticals is notifying its customers of the recall by phone and letters for further notification to their retail stores.  Consumers who have the product with any of the lot numbers listed above should stop use of the product immediately and return it to the place of purchase.  

Consumers with questions regarding this recall can contact Altaire Pharmaceuticals at 1-800-258-2471, Monday – Friday from 9 am – 5 pm ET.  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

 


'/>"/>
SOURCE Altaire Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 Safe Rx ... of pharmacies based in Loveland, Colorado ... Vials (LPVs) in selected Good Day locations.     ... a cost-effective alternative for secure storage," said Milton ... less than the price of a cup of coffee, ...
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, ... for cell and advanced therapies , has announced ... biopharmaceutical company developing "tumor starvation" treatments for acute ... needs. Under the agreement, Invetech will develop systems ... on Erytech,s proprietary ERYCAPS technology platform, which uses ...
(Date:1/18/2017)... , January 18, 2017 After ... people regarding the use of cannabis both for medical and ... are more Americans open to the use of cannabis, but ... sectors. According to Arcview Market Research, the North American legal ... 30% from the previous year. The research projects sales will ...
Breaking Medicine Technology:
(Date:1/18/2017)... Agoura Hills, CA (PRWEB) , ... January 18, ... ... risk of dental problems ranging from gum disease to enamel erosion, and those ... from the Massachusetts Department of Public Health, many pregnant women are failing to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the 2016 ... and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best of ... 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from the ...
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
Breaking Medicine News(10 mins):